Abstract | BACKGROUND: We recently demonstrated that the T-helper type 1 (Th1) immune response plays an important role in the development of non-eosinophilic inflammation induced by airway exposure of an allergen plus double-stranded RNA (dsRNA). However, the role of lipoxygenase (LO) metabolites in the development of Th1 inflammation is poorly understood. OBJECTIVE: To evaluate the role of LO metabolites in the development of Th1 inflammation induced by sensitization with an allergen plus dsRNA. METHODS: A Th2-allergic inflammation mouse model was created by an intraperitoneal injection of lipopolysaccharide-depleted ovalbumin (OVA, 75 microg) and alum (2 mg) twice, and the Th1 model was created by intranasal application of OVA (75 microg) and synthetic dsRNA [10 microg of poly(I : C)] four times, followed by an intranasal challenge with 50 microg of OVA four times. The role of LO metabolites was evaluated using two approaches: a transgenic approach using 5-LO(-/-) and 15-LO(-/-) mice, and a pharmacological approach using inhibitors of cysteinyl leucotriene receptor-1 (cysLTR1), LTB4 receptor (BLT1), and 15-LO. RESULTS: We found that the Th1-allergic inflammation induced by OVA+dsRNA sensitization was similar between 5-LO(-/-) and wild-type (WT) control mice, although Th2 inflammation induced by sensitization with OVA+alum was reduced in the former group. In addition, dsRNA-induced Th1 allergic inflammation, which is associated with down-regulation of 15-hydroxyeicosateraenoic acids production, was not affected by treatment with cysLTR1 or BLT1 inhibitors, whereas it was significantly lower in 12/15-LO(-/-) mice compared with WT control mice. Moreover, dsRNA-induced allergic inflammation and the recruitment of T cells following an allergen challenge were significantly inhibited by treatment with a specific 15-LO inhibitor (PD146176). CONCLUSION: 15-LO metabolites appear to be important mediators in the development of Th1-allergic inflammation induced by sensitization with an allergen plus dsRNA. Our findings suggest that the 15-LO pathway is a novel therapeutic target for the treatment of virus-associated asthma characterized by Th1 inflammation.
|
Authors | S G Jeon, H-G Moon, Y-S Kim, J-P Choi, T-S Shin, S-W Hong, Y-M Tae, S-H Kim, Z Zhu, Y S Gho, Y-K Kim |
Journal | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
(Clin Exp Allergy)
Vol. 39
Issue 6
Pg. 908-17
(Jun 2009)
ISSN: 1365-2222 [Electronic] England |
PMID | 19260872
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 6,11-dihydro-5-thia-11-aza-benzo(a)-fluorene
- Acetates
- Allergens
- Alum Compounds
- Cyclopropanes
- Fatty Alcohols
- Fluorenes
- Glycols
- Leukotriene Antagonists
- Lipoxygenase Inhibitors
- Ltb4r1 protein, mouse
- Quinolines
- RNA, Double-Stranded
- Receptors, Leukotriene
- Receptors, Leukotriene B4
- Sulfides
- ovalbumin-alum
- U 75302
- Ovalbumin
- Arachidonate 15-Lipoxygenase
- Arachidonate 5-Lipoxygenase
- montelukast
- Poly I-C
|
Topics |
- Acetates
(pharmacology)
- Allergens
(immunology)
- Alum Compounds
(pharmacology)
- Animals
- Arachidonate 15-Lipoxygenase
(genetics, immunology, metabolism)
- Arachidonate 5-Lipoxygenase
(genetics, immunology, metabolism)
- Cyclopropanes
- Disease Models, Animal
- Fatty Alcohols
(pharmacology)
- Fluorenes
(pharmacology)
- Glycols
(pharmacology)
- Hypersensitivity
(enzymology, immunology)
- Inflammation
(immunology, metabolism)
- Leukotriene Antagonists
(pharmacology)
- Lipoxygenase Inhibitors
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Knockout
- Ovalbumin
(pharmacology)
- Poly I-C
(immunology)
- Quinolines
(pharmacology)
- RNA, Double-Stranded
(immunology)
- Receptors, Leukotriene
(drug effects, immunology, metabolism)
- Receptors, Leukotriene B4
(antagonists & inhibitors, immunology, metabolism)
- Sulfides
- Th1 Cells
(enzymology, immunology)
- Th2 Cells
(enzymology, immunology)
|